© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
March 30, 2015
Adjustments can be made that would improve and streamline hemophilia care, according to a panel of experts whose discussion was published in Blood Transfusion.
Producers of a von Willebrand factor recombinant treatment are seeking a biologics license after already being granted orphan drug status by the FDA.
Age and quality of life in hemophilia patients is linked, according to research published in Blood Transfusion.
A gene therapy treatment for men with hemophilia B proved effective, and the researchers involved in the study estimate it saved $2.5 million for the trial's patients.
Turoctocog alfa reduced annualized bleeding rates in hemophilia A patients in a phase 3 clinical trial from Novo Nordisk.
Researchers examine the current issues facing hemophilia patients and physicians and potential solutions to the issues in the quarterly journal Blood Transfusion.